GBT Backs Passage of Expansive SCD Treatment Centers Act
Global Blood Therapeutics (GBT) supports the recently introduced Sickle Cell Disease Treatment Centers Act of 2022 (HR 8855/S 4866), which calls for $535 million in annual funding for sickle cell disease (SCD) treatment, research, and education. Introduced on Sept. 15, the legislation would create a national network of…